CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-15 | ROBIN HOWARD W President & CEO | Grant or award · Common Stock | +821,250 | 821,250 | ||
| 2022-05-16 | Zalevsky Jonathan Chief R&D Officer | Sale | −21,673 | $3.95 | $86K | 276,399 |
| 2022-05-16 | Wilson Mark Andrew SVP & General Counsel | Sale | −3,136 | $3.95 | $12K | 117,939 |
| 2022-05-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −5,841 | $3.95 | $23K | 170,427 |
| 2022-05-16 | ROBIN HOWARD W President & CEO | Sale | −36,529 | $3.95 | $144K | 620,941 |
| 2022-05-16 | NORTHCOTT JOHN SVP & Chief Commercial Officer | Sale | −4,592 | $3.95 | $18K | 223,210 |
| 2022-05-16 | Labrucherie Gil M SVP, COO & CFO | Sale | −17,448 | $3.95 | $69K | 312,905 |
| 2022-05-15 | Zalevsky Jonathan Chief R&D Officer | Grant or award | +23,950 | 298,072 | ||
| 2022-05-15 | Thomsen Jillian B. SVP & Chief Accounting Officer | Grant or award | +10,950 | 176,268 | ||
| 2022-05-15 | ROBIN HOWARD W President & CEO | Grant or award | +68,450 | 657,470 | ||
| 2022-05-15 | Labrucherie Gil M SVP, COO & CFO | Grant or award | +28,750 | 330,353 | ||
| 2022-02-16 | Zalevsky Jonathan Chief R&D Officer | Sale | −10,912 | $10.95 | $119K | 274,122 |
| 2022-02-16 | Wilson Mark Andrew SVP & General Counsel | Sale | −3,661 | $10.95 | $40K | 121,075 |
| 2022-02-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −2,363 | $10.95 | $26K | 165,318 |
| 2022-02-16 | ROBIN HOWARD W President & CEO | Sale | −12,480 | $10.95 | $137K | 589,020 |
| 2022-02-16 | NORTHCOTT JOHN SVP & Chief Commercial Officer | Sale | −4,852 | $10.95 | $53K | 227,802 |
| 2022-02-16 | Labrucherie Gil M SVP, COO & CFO | Sale | −7,579 | $10.95 | $83K | 301,603 |
| 2021-12-16 | Zalevsky Jonathan Chief R&D Officer | Grant or award | +52,950 | 285,034 | ||
| 2021-12-16 | Zalevsky Jonathan Chief R&D Officer | Grant or award · Stock Option | +94,000 | 94,000 | ||
| 2021-12-16 | Wilson Mark Andrew SVP & General Counsel | Grant or award | +37,800 | 124,736 |
Page 9 of 18 · 355 trades